Q3 2026 Abbott Earnings Conference Call - LIFECELL CORP

Explicit Guidance:

• Q4 2026: Forecast adjusted EPS of $1.62–$1.67.
• Full Year 2026: Reduced sales growth guidance to ~6% (implied Q4 growth of ~8%).
• Full Year 2027: Anticipate sales growth starting "pretty similar" to 2026 levels (conservative start) with expectation of acceleration during the year; expect double-digit EPS growth, gross margin expansion, and dividend growth.
• Post-Separation (Future): Expect Abbott sales growth to accelerate by 50–100 bps; gross margin % of sales to increase by >200 bps; operating margin % of sales to increase by ~100 bps.
• FX Impact: Expect unfavorable impact of approximately 1% on Q4 2026 sales.

Business-Segment Outlook:

• Diagnostics: View underlying healthcare demand as healthy and durable based on test volume data.
• Cancer Diagnostics: Cologuard growth accelerating in the mid-teens; new blood-based colorectal cancer screening test launched in September expected to contribute to growth (higher ASP than Cologuard); MRD test data presentation at ESMO anticipated as a significant growth driver; Cologuard Plus reimbursement process viewed as favorable (no anticipated cut).
• Electrophysiology (EP): Q4 2026 growth expected at ~20% (down from prior 25% guidance) due to short-term LAA market headwinds (delayed orders for LAA360 pending CE mark); expect growth to reignite in 2027 with LAA360 launch; TactiFlex Duo launching in US Q4 2026; Volt PFA catheter launching in Japan Q4 2026; LAA360 pivotal data at TCT; AMOLED 360 expected to gain market share in Europe and US.
• Diabetes: CGM sales growth expected in "low to mid-single digits" for Q4 and next few quarters due to lack of Type 2 non-insulin reimbursement expansion and international pricing pressure; LibreDuo (dual glucose/ketone sensor) launching in US in December 2026; anticipate strong reimbursement growth upon CMS approval for Type 2 non-insulin users; expect volume growth to be muted by pricing adjustments to maintain 50–70% market share in major international markets.
• Established Pharmaceuticals (EPD): Double-digit growth anticipated in several Asian, Latin American, and Middle Eastern countries; biosimilar portfolio expected to capitalize on LOE in the biologic space; long-term growth rate target of 7.5–8%.
• Nutrition: Spin-off planned to be completed by end of 2027; new independent company expected to be a S&P 500 included entity with $8.5B annual sales; positioned to capitalize on metabolic health trends; Similac whole milk product launched; WIC contract wins driving US pediatric nutrition growth.

Market and Competitive Outlook:

• Nutrition Market: Shift from health professional-led to consumer preference/retail-led; competition from traditional food companies repositioning portfolios; new company expected to be the largest globally scaled pure play in healthy nutrition.
• MedTech: PFA category seeing rapid adoption in US and Europe; LAA market facing short-term headwinds from competitor dynamics and new product waiting; IVL (intravascular lithotripsy) market viewed as billion-dollar growth opportunity.
• Diabetes Market: Intense international competition leading to early pricing pressure; Type 2 non-insulin CGM market expected to accelerate once reimbursement expands (behavioral modification tool).
• Cancer Screening: Market shift toward broader adoption of blood-based testing, though stool-based (Cologuard) remains standard for early detection; Abbott positioning as only company with both stool and blood options.

Macro / Industry Outlook:

• Healthcare Demand: View underlying demand for healthcare as "healthy and durable" based on stable test volumes.
• Regulatory: FDA approvals received earlier than expected for TactiFlex Duo and LibreDuo; CMS reimbursement for Cologuard Plus expected to be favorable.
• Currency: FX headwinds noted for Q4 2026 (approx. 1% impact).
• Litigation: NEU (Similac) litigation matters will remain with Abbott; separation does not require full resolution; both entities well-capitalized to defend legal positions; settlement with 2,000 claimants in August reflects no change in product safety efficacy stance.

Strategic Initiatives:

• Nutrition Spin-off: Executing a tax-free distribution to shareholders; Daniel Salvadori appointed CEO of new nutrition company; separation expected to complete by end of 2027; new company expected to raise debt with proceeds distributed to Abbott; combined dividends will equal current Abbott dividend.
• R&D Investment: R&D spending crossing $3B in 2026 and increasing into 2027; focus on high-growth areas including leadless pacing, mitral replacement, IVL, neuromodulation, lactate sensors, and biosimilars.
• M&A: No impact from spin-off on M&A strategy; future M&A expected to be "tuck-in" rather than transformative; balance sheet remains flexible (net debt/EBITDA ~2x); dividend growth and buybacks remain priorities.
• Product Launches:
  • Q4 2026: TactiFlex Duo (EP), LibreDuo (Diabetes), Cologuard blood test (Diagnostics).
  • 2027: Significant ramp-up of existing 2026 launches; multiple new products in development.
• Post-Separation Financial Profile: Abbott expected to have higher growth and margin profile; Nutrition company expected to have distinct investment requirements.

Risks and Headwinds to Outlook:

• Electrophysiology: Short-term growth slowdown in LAA market due to competitor product dynamics and waiting for Abbott's LAA360 approval.
• Diabetes: Pricing pressure in international markets and lack of Type 2 non-insulin reimbursement expansion impacting volume growth in the near term.
• Cybersecurity: July cyber event caused temporary 1% growth drag in diagnostics due to connectivity issues; potential for future disruptions.
• Regulatory/Reimbursement: Uncertainty regarding timing of CMS reimbursement expansion for Type 2 non-insulin CGM use.
• Litigation: Ongoing neonatal nutrition litigation (NEU) requiring capital and management attention, though not a prerequisite for spin.
• Macro: FX volatility impacting sales growth.

Management Tone on the Future:

• Confidence: High confidence in Abbott's future as an innovation-driven healthcare company and in the independent nutrition company's potential to be a "market shaper."
• Strategy: Shift to a "conservative" top-line guidance approach for 2027 to ensure delivery and opportunity for upside, while maintaining a track record of meeting/beating EPS targets.
• Differentiation: Emphasis on a balanced portfolio of high-growth, high-margin businesses aligned with aging population and chronic disease trends.
• Execution: Management expresses strong confidence in the team's ability to execute the separation and drive margin expansion through R&D productivity.

Miscellaneous:

• Separation Costs: Expected to be treated as specified items excluded from adjusted earnings; no expected impact on 2026 guidance provided in January.
• Share Count: Final share distribution ratio for the nutrition spin-off to be communicated prior to separation.
• Credit Ratings: Both companies will maintain investment-grade credit ratings post-separation.
• Dividends: Abbott expects to grow the dividend in 2027; combined dividends of both entities post-spin will equal the current Abbott dividend.